Ferring Launches 3 New Clinical Trials for Marketed Bladder Cancer Gene Therapy Adstiladrin
Ferring Pharmaceuticals has launched 3 new clinical trials for nadofaragene firadenovec (Adstiladrin), a marketed adeno-associated virus (AAV) vector-based gene therapy currently approved for the treatment of adult patients with high-risk, Bacillus …